Page results
-
At University College London Hospitals NHS Foundation Trust (UCLH) we value our reputation for top quality care and financial probity and conduct our business in an ethical manner.
-
Swapping the standard blue curtains for sunny yellow ones has made our postnatal ward feel brighter and less clinical.
-
Patient information who have been recommended to use a Biatain® dressing on your skin that has broken down due to your radiotherapy or proton beam therapy treatment.
-
Participants reacted quicker and made fewer errors during menstruation, despite believing their performance would be worse, according to new research from UCL and the Institute of Sport, Exercise & Health (ISEH).
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
This information is for patients having gynaecology surgery who may also need bowel (colorectal) surgery as part of their cancer treatment.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
File results
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0357 - Multiple myeloma treatments
-
FOI/2024/0360 - Radiology Information System (RIS) supplier/ contract/ staff details
-
FOI/2024/0361 - Recording RTT waiting times: Planned patients guidance
-
FOI/2024/0363 - Freedom of Information responses available for Mesh requests
-
FOI/2024/0365 - Specialist clinical systems to manage patients and patient clinical notes